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BACKGROUND AND PURPOSE
TREK two-pore-domain potassium (K2P) channels play a critical role in regulating the excitability of somatosensory nociceptive
neurons and are important mediators of pain perception. An understanding of the roles of TREK channels in pain perception and,
indeed, in other pathophysiological conditions, has been severely hampered by the lack of potent and/or selective activators and
inhibitors. In this study, we describe a new, selective opener of TREK channels, GI-530159.
EXPERIMENTAL APPROACH
The effect of GI-530159 on TREK channels was demonstrated using 86Rb efﬂux assays, whole-cell and single-channel patch-clamp
recordings from recombinant TREK channels. The expression of K2P2.1 (TREK1), K2P10.1 (TREK2) and K2P4.1 (TRAAK) channels
was determined using transcriptome analysis from single dorsal root ganglion (DRG) cells. Current-clamp recordings from
cultured rat DRG neurons were used to measure the effect of GI-530159 on neuronal excitability.
KEY RESULTS
For recombinant human TREK1 channels, GI-530159 had similar low EC50 values in Rb efﬂux experiments and electrophysio-
logical recordings. It activated TREK2 channels, but it had no detectable action on TRAAK channels nor any signiﬁcant effect on
other K channels tested. Current-clamp recordings from cultured rat DRG neurones showed that application of GI-530159 at
1 μM resulted in a signiﬁcant reduction in ﬁring frequency and a small hyperpolarization of resting membrane potential.
CONCLUSIONS AND IMPLICATIONS
This study provides pharmacological evidence for the presence of mechanosensitive TREK K2P channels in sensory neurones and
suggests that development of selective K2P channel openers like GI-530159 could aid in the development of novel analgesic
agents.
Abbreviations
BL-1249, (5,6,7,8-tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine; CAPE, caffeic acid phenylethyl ester;
CDC, cinnamyl 1,3,4-dihydroxy-α-cyanocinnamate; DRG, dorsal root ganglion; GI-530159, 4,40-
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Introduction
TWIK-related K (TREK) channels are mechanosensitive
ion channels, which are members of the two-pore-domain
(K2P) potassium channel family (Enyedi and Czirjak, 2010;
Feliciangeli et al., 2015; Renigunta et al., 2015). They
contribute to background potassium conductances in many
neurons and other cell types. Their activity can be regulated
by a number of different physical and chemical stimuli,
which include membrane stretch, membrane depolarization,
heat, arachidonic acid and other polyunsaturated fatty acids
(see Honoré, 2007; Noël et al., 2011; Mathie and Veale,
2015). There are three members of the TREK subfamily
(Enyedi and Czirjak, 2010), TREK1 (K2P2.1; KCNK2), TREK2
(K2P10.1; KCNK10) and TRAAK (K2P4.1, KCNK4), which
share many structural and functional properties. At least in
expression systems, recent evidence suggests that all three
channels can form functional heterodimeric channels with
each other (Blin et al., 2016; Lengyel et al., 2016; Levitz
et al., 2016).
Increasing evidence points to an important contribution
from a number of different potassium channels (see Du and
Gamper, 2013; Tsantoulas and McMahon, 2014; Waxman
and Zamponi, 2014), including K2P channels (Alloui et al.,
2006; Woolf and Ma, 2007; Noël et al., 2009; Mathie, 2010;
Plant, 2012), in pain processing. Among K2P channels, the
strongest body of evidence from both expression functional
studies highlights the importance of TREK1, TREK2 and also
TRESK channels (see Mathie and Veale, 2015).
TREK1 channels are expressed in both small-sized and
medium-sized dorsal root ganglion (DRG) neurons where
they are often co-localized with excitatory transient receptor
potential cation channel subfamily V member 1 (TRPV1)
channels (Maingret et al., 2000; Talley et al., 2001; Alloui
et al., 2006; Dedman et al., 2009; Marsh et al., 2012), and
enhanced expression of TREK1 is seen in DRG neurons in a
mouse model of neuropathic pain (Han et al., 2016). TREK1
knockout mice are more sensitive than wild-type mice to
painful heat sensations near the threshold between
non-painful and painful heat (Alloui et al., 2006). More
recently, it has been shown that the TLR7 receptor agonist,
imiquimod, enhances the excitability of DRG neurons, at
least in part, through blocking TREK1 channels (Lee et al.,
2012). The pain-relieving actions of morphine may be linked
to TREK1 channel activity since morphine, acting through μ
receptors, has been shown to enhance TREK1 current
directly, and TREK1 knockout mice showed signiﬁcantly less
morphine-induced analgesia than wild-type animals
(Devilliers et al., 2013). Taken together, this evidence suggests
that TREK1 is a channel critical for regulating the excitability
of somatosensory nociceptive neurons and, therefore, pain
perception.
TREK2 channels have also been implicated in regulating
somatosensory nociceptive neuron excitability (Acosta et al.,
2014; Pereira et al., 2014). For example, TREK2 channels
may be distinctively expressed in a subpopulation of
thermosensitive neurons and regulate the perception of
moderate temperature changes by altering the ﬁring activity
of certain sensory C ﬁbres (Pereira et al., 2014).
A deeper understanding of the roles of TREK channels in
pain perception and, indeed, in a number of other
pathophysiological conditions, has been severely hampered
by the lack of potent and/or selective activators and
inhibitors. Up until now, the only known commercially
available TREK channel activator is BL-1249, originally
identiﬁed as a putative activator of TREK1-like currents in
human bladder myocytes (Tertyshnikova et al., 2005). Subse-
quently, this compound was shown to activate TREK1 and
TREK2 channels directly (Veale et al., 2014; Dong et al.,
2015); however, this compound lacks the selectivity required
for it to be useful, in isolation, as an indicator of TREK
channel activity (see Results). Other activators of TREK
channels have been described including ML67-33
(Bagriantsev et al., 2013) and a number of caffeic acid esters
(Danthi et al., 2004; Rodrigues et al., 2014; Vivier et al.,
2017) (see Discussion).
In this study, we describe a new, selective opener of TREK
channels, GI-530159, and show that it reduces the excitabil-
ity of small DRG neurons. A preliminary account of some of
this work has been given previously (Loucif et al., 2015).
Methods
86Rubidium efflux studies
CHO–hTREK1 cells were plated on 96-well, tissue culture-
treated clear plates (92 696) the day before the assay and
incubated overnight at 37°C in the presence of 1 μCi·mL1
86Rubidium (Rb, NEZ072, Perkin Elmer, Waltham MA, USA).
Prior to commencement of the assay, the 86Rb spiked media
were removed from the plate, and cells were washed four
times with 100 μL of a 5 mM K+ ‘Earle’s balance salt solution’
(EBSS) buffer containing 135 mMNaCl, 5.4 mM KCl, 1.8 mM
CaCl2, 0.8 mM MgCl2,10 mM HEPES and 5 mM glucose,
pH 7.4 (adjusted with NaOH). After the last wash, the buffer
was removed, replaced with 100 μL of either 5 mM K+ EBSS
alone or containing different concentrations of GI-530159
or 70 mM K+ EBSS [containing 70 mM NaCl, 70 mM KCl,
1.8 mM CaCl2, 0.8 mMMgCl2, 10 mM HEPES and 5 mM glu-
cose, pH 7.4 (adjusted with NaOH)], alone or containing ref-
erence inhibitor 100 μM CP-338818 (C2499, Sigma-Aldrich,
St Louis MO, USA). After plate was incubated for 60 min at
room assay, buffer was removed from the plates and trans-
ferred to a counting plate. The cells were then lysed with
100 μL of 0.1% SDS, and the lysate transferred to a second
counting plate. Both counting plates were then read on the
Wallac Microbeta to measure 86Rb content [counts per min
(CPM)]. % 86Rb efﬂux values were calculated as follows:
86Rb efflux %cell contentð Þ ¼ CPM in efflux bufferð Þ=ð
CPM in efflux bufferð
þCPM in cell lysateÞÞ100:
Magnitude of 86Rb efﬂux stimulation was calculated as
follows:




Efflux in 70 mM Kþ EBSS

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Half maximal activation of 86Rb efﬂux (EC50) value was
calculated using IDBS Xlﬁt using a four-parameter logistic
equation and expressed as mean ± SEM.
Electrophysiological recordings
Electrophysiological studies were performed on CHO or
HEK293 cells, stably expressing human recombinant TREK1;
tsA-201 cells transiently transfected with human recombi-
nant K2P channels and acutely dissociated rat DRG cells, all
at room temperature (22–24°C).
Automated whole-cell voltage clamp
Automated patch-clamp studies were performed with the
Qpatch Sophion Bioscience A/S (Ballerup, Denmark)
automated patch-clamp platform. Sixteen-well Qplates were
loaded with CHO cells stably expression human recombinant
TREK1 (CHO–TREK1 cells) in external buffer containing (in
mM) 148NaCl, 5 KCl, 1 CaCl2, 1MgCl2, 10 HEPES and 10 glu-
cose. Internal recording solution was (in mM) 100 K gluco-
nate, 40 KCl, 1 MgCl2, 10 BAPTA, 10 HEPES and 1 MgATP.
Whole-cell recording from HEK293 cells stably
expressing TREK1
Studies were performed using a conventional patch clamp
and Multiclamp 700B and pCLAMP software (Molecular
Devices, Sunnyvale, CA, USA). For conventional manual
patch clamp, glass coverslips containing HEK293 cells were
perfused with an extracellular solution (ECS) containing (in
mM): 135 NaCl, 4.7 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES and
10 glucose, pH 7.4, with NaOH (310 mOsmol·L1). The patch
pipette was ﬁlled with (in mM): 130 KCl, 1 MgCl2, 5 MgATP,
10 HEPES and 10 BAPTA, pH adjusted to 7.3 with KOH
(290 mOsmol·L1).
Single-channel recordings
Human TREK1 single channels were recorded in excised
inside-out membrane patches using an Axopatch 200B
patch-clamp ampliﬁer and pCLAMP 10 software. Inside-out
membrane patches were excised from HEK293 cells express-
ing human TREK1 channels. Sylguard® 184-coated glass
pipettes with resistance around 10–15 MΩ were used. Pipette
and bath compositions for inside-out patches were opposite
to those used in voltage-clamp, that is, the pipette solution
on the extracellular face of the channels contained 130 mM
K and the bath solution on the intracellular face of the
channel contained 4.7 mM K. Channel activities were
recorded at +60 mV. The action of a hTREK1 opener was
tested by addition to the intracellular solution. Single-
channel records were ﬁltered with an eight-pole Bessel ﬁlter
(model LHBF-48X, npi electronic GmbH, Tamm, Germany)
at a corner frequency (fc) of 2 kHz and acquired using a
DigiData 1440A interface and pCLAMP 10 software at a
sampling rate of 20 kHz. Single-channel traces were
generated without further ﬁltering.
Whole-cell recording from tsA-201 cells
transiently expressing TREK1 and other K2P
channels
Recordings of hTREK1, hTREK1∆N, hTREK2, hTRAAK and
hTHIK1 (K2P13.1) currents from transiently transfected
tsA-201 cells were performed using methods as described in
Veale and Mathie (2016). Brieﬂy, the pcDNA3.1 vector was
cloned with the gene of interest, and these vectors and a
similar vector containing GFP were incorporated into the
tsA201 cells (0.5 μg per well) using the calcium phosphate
method. The cells were incubated for 6–12 h at 37°C in 95%
oxygen and 5% carbon dioxide. Cells were then washed using
a PBS solution and used for experiments after 24 h.
Currents were recorded using whole-cell patch-clamp
using an Axopatch 1D ampliﬁer. Cells were placed in a record-
ing chamber ﬁlled with an external medium composed of
145 mM, NaCl, 2.5 mM KCl, 3 mM MgCl2, 1 mM CaCl2 and
10mMHEPES (pH to 7.4, using NaOH). The internal medium
used in the glass pipette comprised 150 mM KCl, 3 mM
MgCl2, 5 mM (or 0.1 mM) EGTA and 10 mM HEPES (pH to
7.4, using KOH). GI-530159 was applied by bath perfusion.
Currents were recorded and analysed using pCLAMP 10.2
software Microsoft Excel. The voltage protocol used for
recording current through K2P channels was as previously
described (Veale and Mathie, 2016). For analysis, we
measured the current difference between the 80 and
40 mV steps.
Recordings from dorsal root ganglion neurons
Acutely dissociated rat DRG cells were obtained according to
a previously described protocol (Passmore, 2005). All animal
care and experimental procedures complied with guidelines
and were approved by the Pﬁzer Neusentis Institutional
Animal Use and Care Committee. Animal studies are reported
in compliance with the ARRIVE guidelines (Kilkenny et al.,
2010; McGrath and Lilley, 2015).Cells were plated on coated
coverslips (poly-D-lysine/laminin, BD Biosciences, San Jose,
CA, USA) prior to patching on the same day. Cells were
perfused with an extracellular solution containing (in mM):
135 NaCl, 4.7 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES and 10
glucose, pH 7.4, with NaOH (310 mOsmol·L1). Pipette
solution contained (in mM): 130 KCl, 1 MgCl2, 5 MgATP, 10
HEPES and 5 EGTA, pH adjusted to 7.3 with KOH
(290 mOsmol·L1). For whole-cell recordings, currents were
ﬁltered at 2 kHz and sampled at 5 kHz. Series resistance was
compensated for by up to 80%. For current-clamp recordings,
action potential ﬁring and restingmembrane potential (RMP)
were recorded from small cells (<30 pA). GI-530159 was
dissolved in 0.3% DMSO as 10 mM stock and applied in the
vicinity of cells using a gravity fed perfusion system
(MSC-200, Bio-Logic SAS, Claix, France).
Data were analysed using pCLAMP or Qpatch software or
Spike2 (Cambridge Electronic Device, Cambridge, UK) and
Prism 6.0 (GraphPad, San Diego, CA, USA) software.
Transcriptome analysis from single DRG cells
Lumbar DRGs from four rats were dissociated then passed
through a BSA gradient. Individual cells were loaded onto
Fluidigm C1 17–25 μm size chips for single-cell preparation.
Three replicates were performed. Cell collection chambers
were viewed down the microscope to exclude any that had
multiple cells/chunks of debris. The C1 lysed, reverse
transcribed and preampliﬁed the cells, using the SMARTseq
protocol. Sequencing libraries were prepared and
multiplexed 96 ways using the Nextera XT kit (Illumina, San
Diego CA, USA). Libraries were quantiﬁed using the Qubit
GI-530159 activates TREK K2P channels BJP
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High Sensitivity DNA assay (Thermo Fisher Scientiﬁc,
Waltham MA, USA) and library quantiﬁcation kits (KAPA
Biosystems, Wilmington MA, USA) and pooled in equal
amounts for single-end sequencing on an Illumina Nextseq
500. Sequencing data were aligned, and gene level expression
measured using spliced transcripts alignment and reconstruc-
tion tool (Dobin et al., 2013) and assigned to genomic
features using featureCounts (Liao et al., 2014) and Ensembl
gene annotations. Gene read counts were converted to
fragments per kilobase per million (FPKM) and log2
transformed. In total, ~180 cells were successfully processed
of which 120 were deﬁned as neurons, based on marker
expression.
Group sizes
The exact group size (n) for each experimental
group/condition is provided, and ‘n’ refers to independent
values, not replicates. Data subjected to statistical analysis
have n of at least ﬁve per group.
Randomization
When comparisons are made between different recording
conditions or different, mutated, forms of a channel, record-
ings were alternated between one condition and the other
on a given day.
Blinding
No blinding was undertaken in this study. It is not a usual
procedure for this form of study and cannot be applied
retrospectively.
Normalization
Normalization of responses was carried out in some experi-
ments (Rb ﬂux experiments and some electrophysiological
experiments) to allow comparison with standardized re-
sponses and to minimize the inﬂuence of variable baseline
levels of current activity on comparisons of percentage en-
hancements between one experimental platform and
another.
Statistical comparison
Group mean values and statistical analysis used independent
values. When comparing groups, a level of probability
(P < 0.05) was deemed to constitute the threshold for statisti-
cal signiﬁcance. For statistical comparisons of currents in the
absence and presence of GI-530159 (1 μM) (Figures 3 and 5),
each n value represents a recording from a cell on an indepen-
dent coverslip on different recording days. Comparisons were
made using two-tailed paired t-tests. To compare the degree of
enhancement by GI-530159 (1 μM) between TREK1, TREK2
and TREK1∆N channels (Figure 5D), one-way ANOVA,
followed by a Dunnett’s multiple comparisons test was used.
In Figure 7D, E, we compared the membrane potential before
and after addition of GI-530159 (1 μM) in 14 neurons from
seven different DRG preparations (seven different animals).
Comparisons were made using two-tailed paired t-tests both
for each of the 14 neurons (n = 14, Figure 7D) and for the
averaged response in neurons from a single animal to give
n = 1 for each animal used (so n = 7 animals, Figure 7E).
Statistical analyses were carried out using Graphpad Prism
6.0 (Graphpad). The data and statistical analysis comply with
the recommendations on experimental design and analysis
in pharmacology (Curtis et al., 2015).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetophar-
macology.org, the common portal for data from the
IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al.,
2016), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b).
Results
Activation of recombinant TREK channels by
GI-530139
The structure of GI-530139 (originally ICA-069771) is shown
in Figure 1. The compound has not previously been shown to
have an effect on any identiﬁed biological target, but it is
available commercially (Sigma-Aldrich) as a primary amide
for generating non-stick coatings.
GI-530159 was originally identiﬁed as a putative TREK1
channel activator using an 86Rb screen of a CHO–hTREK1 cell
line (Figure 2). Figure 2A shows exemplar values for 86Rb
efﬂux from CHO–hTREK1 cells after a 60 min exposure to
either normal (5 mM K) external solution, a high potassium
(70mMK) solution in the absence and presence of a reference
inhibitor (100 μM CP-338818) or the presence of increasing
concentrations of GI-530159 in normal external solution.
86Rb efﬂux is expressed as % of total cell content at beginning
of experiment. The concentration–response relationship for
86Rb efﬂux by GI-530159 (normalized to the response
observed with 70 mM K) is shown in Figure 2B. From a ﬁt of
the logistic equation to the data, the maximum effect of
GI-530159 was 142 ± 2% of that seen with 70 mM K, and
the EC50 for the compound was 0.76 ± 0.1 μM.
Figure 3 shows the effect of GI-530139 on hTREK1
channel currents in HEK293 cells recorded using conven-
tional manual patch clamp. The enhancement of current is
illustrated for 1 μM GI-530139 (Figure 3A) and can be seen
both in the voltage step from 80 to 0 mV and in the voltage
ramp from 100 to +80 mV (Figure 3B). The current–voltage
relationship for GI-530139 enhanced current was obtained
by subtracting the current in the absence of the compound
(but in the presence of the compound vehicle, DMSO) from
that obtained in its presence. This is shown as an inset to
Figure 3B and illustrates that the TREK1 current is enhanced
at all voltages by GI-530139 and that the enhanced current
is outwardly rectifying. The GI-530139-enhanced current
reverses close to 80 mV, and there is clear increased
current at voltages between 70 and 40 mV by GI-530139,
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potential of small DRG neurons (see Figure 7, below). Current,
measured at 0mV,was signiﬁcantly increased from116 ± 15 pA
in the presence of DMSO to 4090 ± 878 pA following addition
of 1 μM GI-530139 (n = 6, P < 0.05, paired t-test, Figure 3C).
The same concentration of GI-530139 is also effective at
reversibly enhancing current through hTREK1 channels in
stably transfected CHO cells, recorded using the Qpatch
automated patch-clamp system (Supporting Information
Figure S1) and hTREK1 channels transiently expressed in
tsA-201 cells (Figure 5A), although for these two latter
platforms, the percentage enhancement is lower, at least in
part because basal current activity is higher (see Discussion).
The activity of single hTREK1 channels measured at
+60 mV in the inside-out manual patch conﬁguration are
enhanced by GI-530139 (Figure 3D). From the traces, it can
be seen that the single-channel current amplitude was not
altered by application of GI-530139 (10 μM) to the intracellu-
lar side of themembrane, rather the channel open probability
was increased. In the recording from which these exemplar
traces were taken, the open probability increased from 0.009
to 0.025 following application of GI-530139. Enhancement
of channel open probability by GI-53019 was observed in 12
inside-out patch recordings, three of which contained just a
single active TREK-1 channel. This provides strong evidence
that GI-530139 acts directly on TREK1 channels to enhance
current rather than acting indirectly through a second mes-
senger pathway. This is similar to the direct action on TREK
channels shown previously for BL-1249 (Dong et al., 2015).
Concentration–response data were obtained for
GI-530139 over a range of concentrations from 0.1 to
30 μM, measured at 0 mV. These data show that GI-530139 at
10–30 μM can maximally activate the channel (Figure 4A, B)
with a GI-530139 enhanced current of 6.6 ± 0.9 nA (n = 5) at
30 μM. This can be compared with a maximal enhanced cur-
rent by BL-1249 at 100 μM of 7.2 ± 1.3 nA (n = 7) (Figure 4C).
A ﬁt of the concentration–response curve for GI-530139 gives
an EC50 of 0.89 ± 0.3 μM, very close to that seen for the Rb
efﬂux data above (0.76 μM, Figure 2B). By comparison,
BL-1249 has an EC50 of around 1 μM in electrophysiological
experiments (Cao et al., 2010). Thus, the extent of TREK1
channel activation is similar between GI-530139 and BL-
1249, and both compounds show similar potency.
The compounds do, however, show important differences in
their selectivity as shown by studies using both manual patch-
clamp and ﬂux assay platforms. Within K channel families,
BL-1249 has a signiﬁcant effect on other ion channels, which
is not seen with GI-530139. For example, BL-1249 produces
signiﬁcant inhibition of BK (KCa1.1), Kv7.2 (KCNQ2),
Kv7.3(KCNQ3) and NaV1.7 channels at a concentration of
10 μM. By contrast, using manual patch clamp in recombinant
cell lines, the following effects were observed against other po-
tassium channels with GI-530139 at 10 μM: K2P18.1 (TRESK;
2.0 ± 3.5%, n = 4), KCa1.1 (BK; 3.3 ± 6.7%, n = 4) and Kv11.1
(hERG:7.3 ± 5.1%, n = 5). Furthermore, GI-530139 had no ac-
tivator effects on other potassium channels TASK2 (K2P5.1),
Kv7.1, Kv7.2 and Kv7.3 using Rb
+ efﬂux assays or against sodium
channels NaV1.2, NaV1.7 and NaV1.8 (EC50>100 μM).
In addition to activating TREK1 channels, BL-1249 is a
strong activator of TASK3 (K2P9.1) channels (see Cao et al.,
2010). By contrast, GI-530139 had negligible effect on TASK3
Figure 2
Effect of GI-530159 on
86
Rb ﬂux through TREK1 channels. (A) Exemplar values of
86
Rb efﬂux from 96-well plate containing monolayers of
CHO–hTREK1 during 60 min exposure to normal 5 mM K EBSS buffer, 70 mM K buffer, 70 mM KCl buffer and reference inhibitor (100 μM
CP-338818) as well increasing concentrations of GI-530159 made up in 5 mM K EBSS buffer.
86
Rb efﬂux is expressed as % of cell content at
beginning of experiment (n = 3 for each concentration of GI-530159, n = 24 for 5 mM K buffer). (B) Concentration-dependence of stimu-
lation of
86
Rb efﬂux by GI-530159 normalized to the response observed with 70 mM K EBSS buffer. Maximal ﬂux (142 ± 2%) and EC50
(0.76 ± 0.1 μM) were derived from ﬁt of logistic equation to data.
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channels at a concentration (1 μM) that is around 50% effec-
tive at activating TREK1 channels, with an activated current
of 0.02 ± 0.005 nA (n = 5) for TASK3 channels compared with
4.0 ± 0.9 nA (n = 6) for TREK1 channels.
However, within the TREK family, GI-530139 is not
completely selective for TREK1 channels. Figure 5A, D shows
activation of TREK1 channels transiently transfected into
tsA-201 cells by GI-530139 (1 μM, 69 ± 12%, n = 6). The
Figure 3
Effect of GI-530159 on stably transfected TREK1 channel currents. (A) Whole-cell current recordings of TREK1 channels stably transfected in
HEK293 cells, in the presence (blue) and absence (green) of GI-530159 (1 μM). (B) Current–voltage relationship for TREK1 currents in the pres-
ence (blue) and absence of GI-530159. The inset shows the current–voltage relationship for GI-530159-activated current. (C) Control current,
measured at 0 mV (green), was signiﬁcantly enhanced by 1 μMGI-530139 (blue, n = 6, *P< 0.05, paired t-test). Each n value represents a record-
ing from a cell on an independent coverslip on different recording days. (D) Representative single-channel records of hTREK-1 in excised inside-
out membrane patches (12 inside-out patch recordings in total) from HEK293 cells in the presence and absence of GI-530159 (10 μM). Dotted
line indicates the closed channel state, and upward deﬂections correspond to channel openings. Membrane patches were voltage clamped at
+60 mV at room temperature.
Figure 4
Concentration–response curve for GI-530159 on stably transfected TREK1 channels. (A) Representative example of cumulative
concentration–response curve for GI-530159 on TREK1 current stably transfected in HEK293 cells. Current was measured at 0 mV.
(B) Concentration–response curve reveals EC50 of 0.9 μM for GI-530159 (n = 6 for each concentration). Each n value represents a recording from
a cell on an independent coverslip on different recording days. (C) Maximum current enhancement by GI-530159 (n = 6) is similar to that seen for
BL-1249 (n = 7) for TREK1 currents in stably transfected HEK293 cells.
BJP
A J C Loucif et al.
6 British Journal of Pharmacology (2017) •• ••–••
percentage enhancement by GI-530139 in these cells is much
smaller than that seen in stably transfected HEK293 cells but
comparable with that seen in automated patch recordings for
stably transfected CHO cells (Supporting Information Figure
S1), primarily because of differences in basal current level.
The enhancement of TREK2 channels by 1 μM GI-530139 in
transiently transfected tsA-201 cells was 42 ± 6%, n = 6
(Figure 5B, D). TRAAK channels are not activated by 1 μM
GI-530139 (Figure 5C, D, 2 ± 10%, n = 7), and there is no
detectable effect on TRAAK channels even at a concentration
of 10 μM (see Figure 5C), in contrast to the clear enhance-
ment of TRAAK channels seen with BL-1249 (Supporting
Information Figure S2). GI-530139 produces activation of
the short form of TREK1 channels (TREK1ΔN), formed by
alternative translation initiation (Thomas et al., 2008; Veale
et al., 2010; Veale et al., 2014) (Figure 5D–F). The enhance-
ment of TREK1ΔN channels was 377 ± 57% (n = 5). The degree
of enhancement of current through TREK1 channels was
found to be not signiﬁcantly different from that through
TREK2 channels but was signiﬁcantly smaller than that
through TREK1∆N channels (one-way ANOVA, followed by
Dunnett’s multiple comparisons test, signiﬁcance at the
0.05 level). It is not clear to what degree this differential effect
between TREK1 and TREK1∆N is due to the much smaller
background activity of TREK1∆N channels. We observed no
effect of GI-530159 on THIK1 (K2P13.1) channels (1 μM,
0 ± 3%, n = 7).
TREK channel expression in DRG neurons
There are two major classes of nociceptive somatosensory
neuron, the A ﬁbres, which are lightly myelinated and have
intermediate to large cell body sizes, and C ﬁbres, which are
unmyelinated and have smaller cell bodies (Tsantoulas and
McMahon, 2014). C ﬁbres can be subdivided, based on the
expression of neuropeptides such as substance P, binding to
the plant lectin IB4, or expression of thermosensitive TRP
channels (Tsunozaki and Bautista, 2009). Acute localized
pain is primarily transmitted by Aδ ﬁbres, whilst diffuse pain,
including itch, is mediated by C ﬁbres (Plant, 2012).
Previous work suggests that TREK1 channels are expressed
in both small-sized and medium-sized DRG neurons where
they are often co-localized with excitatory TRPV1 channels
(see Introduction), whilst TREK2 channels have been shown
to be selectively expressed in IB4 binding (non-peptidergic)
C nociceptors (Acosta et al., 2014).
Single-cell RNA sequencing was used to characterize
TREK1, TREK2 and TRAAK expression levels in individual rat
DRG neurons. Of 180 cells processed, 120 were classiﬁed as
neuronal based on marker expression. These neurons were
then clustered into three distinct subtypes (peptidergic C
ﬁbre, non-peptidergic C ﬁbre or A ﬁbre) deﬁned by the expres-
sion of a variety of marker genes. The panels on the right-
hand side of Figure 6B and Supporting Information Figures
S3 and S4 show the expression of three key markers [Calca
(calcitonin-related polypeptide α), P2rx3 (P2X3 re-
ceptor), Scn8a (NaV1.6)] across all 120 cells divided into
those three groups. The y-axis is a normalizedmeasure of gene
expression (log-transformed FPKM), and the three boxes
indicate the median expression of the gene within a given
cluster and the 25th–75th quantiles of the expression. The
whiskers and individual points show the expression in ‘out-
lier’ cells. For the indicated markers, Calca expression is the
Figure 5
Effect of GI-530159 on TREK1, TREK2, TRAAK and TREK1ΔN channels transiently transfected in tsA-201 cells. (A, B) GI-530159 activates TREK1 and
TREK2 channels transiently transfected in tsA-201 cells. (C) GI-530159 has no detectable activation of TRAAK channels. (D) Effect of GI-530159 on
TREK1 (n = 6), TREK2 (n = 6), TRAAK (n = 7) and TREK1ΔN (n = 5) channels in transiently transfected tsA-201 cells. (E, F) GI-530159 activates
TREK1ΔN channels. Each n value represents a recording from a cell on an independent coverslip on different recording days. The degree of
enhancement of current through TREK1 channels was found to be not signiﬁcantly different from that through TREK2 channels but was signiﬁ-
cantly smaller than that through TREK1ΔN channels (one-way ANOVA, followed by Dunnett’s multiple comparisons test; P<0.05).
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highest in peptidergic C ﬁbres, P2rx3 is the highest in non-
peptidergic, small diameter C ﬁbres and Scn8a is the highest
in A ﬁbres.
For the TREK K2P family members, TREK1 is expressed in
non-peptidergic C ﬁbres, expression within peptidergic C
ﬁbres is variable, whilst expression in A ﬁbres is low
(Figure 6A). For TREK2, there is low expression in non-
peptidergic C ﬁbres but greater expression in A ﬁbres
(although variably) and variable expression within
peptidergic C ﬁbres (Supporting Information Figure S3).
Expression of TRAAK is quite variable within each subtype
(Supporting Information Figure S4).
Reduction in DRG neuron excitability by
GI-530139
Using current-clamp recordings from small rat DRG neurones
in short-term culture, application of GI-530139 at 1 μM (close
to the EC50 for GI-530139 on TREK1 channels) resulted in a
signiﬁcant hyperpolarization of the RMP of these neurons
from 53.6 ± 1.5 to 57.1 ± 1.5 mV (n = 14 individual
neurons, P < 0.05, paired t-test, Figure 7A, D, F) and from
54.0 ± 2.0 to 57.8 ± 1.4 mV (n = 7 rats, P < 0.05, paired
t-test, Figure 7E). An exemplar DRG neuron is illustrated in
Figure 7A, which ﬁred repeated action potentials following a
15 pA depolarizing current injection. Following application
of GI-530139 (1 μM), however, the membrane potential was
hyperpolarized, and 15 pA of depolarizing current injection
no longer evoked action potential ﬁring. Overall, application
of GI-530139 led to a reduction in cell ﬁring frequency in
response to depolarizing current injection (15 pA). However,
the effects on cell ﬁring were variable from cell to cell
(Figure 7B, C). Of the 14 cells tested, six showed a complete
abolition in ﬁring frequency in the presence of GI-530139
whilst two showed a reduction. The ﬁring of six neurons
(43%), however, was unaltered following application of
GI-530139 (Figure 7C). The six cells with no change in ﬁring
are shown in blue in Figure 7C, F, whilst the six cells with
abolition of ﬁring are shown in red in Figure 7C, F.
A similar effect on DRG neuron ﬁring was observed with
BL-1249 (Cao et al., 2010). However, these data are more
difﬁcult to interpret because of the lack of selectivity for
TREK channels seen with BL-1249. Indeed, in voltage-clamp
recordings from DRG neurons, a clear block of Na current
was seen with BL-1249 (an effect not observed with
GI-530139), which would contribute to effects on ﬁring
and compromise interpretation of results with this
compound.
Discussion
In this study, we describe a novel activator of TREK potassium
channels, GI-530139. GI-530139 produces a large maximal
enhancement of TREK1 channels with a sub-micromolar
EC50. It has improved selectivity for TREK channels over
existing compounds such as BL-1249, and its effect on
recombinant hTREK1 channels is seen across several assay
platforms including 86Rb ﬂux assays and automated and
manual patch-clamp recordings from different expression
systems. Within the TREK family, GI-530139 activates both
TREK1 and TREK2 channels but has no effect on TRAAK
Figure 6
Single DRG neuron transcriptome – TREK1 channels. (A) Differential TREK1 expression in single peptidergic C ﬁbres, non-peptidergic C ﬁbres and
A ﬁbres. (B) Comparative expression of selective markers for peptidergic C ﬁbres (Calca), non-peptidergic C ﬁbres (P2rx3) and A ﬁbres (Scn8a).
Expression is given as log2 FPKM. Data are from 120 individual DRG neurons isolated from four rats.
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channels. A concentration of 1 μM is sufﬁcient to substan-
tially enhance current through TREK1 channels across the
entire voltage range, including around the resting potential
of mammalian neurons such as DRG neurons. Activation of
postsynaptic TREK1 channels by a selective activator such as
GI-530159 would hyperpolarize the membrane of DRG neu-
rons and depress neuronal activity in the pain pathway sug-
gesting that such compounds may have potential
therapeutic value in the treatment of pain.
From the data in this study using a variety of assay plat-
forms, it is clear that the basal level of activity of TREK1 varies
from one assay system to another and, as a consequence, this
inﬂuences the percentage enhancement of TREK1 current
observed. For stably expressed channels in HEK-293 cells,
basal activity of TREK1 channels was very small, so the
percentage enhancement seen was large. However, for tran-
siently expressed channels in tsA-201 cells and stably
expressed channels in CHO cells for both automated patch
and ﬂux assay systems, basal channel activity is higher, and
the percentage enhancements seen are lower but consistent
across assays. It is not clear why these differences in basal
activity occur between expression systems, but it is important
to note that clear enhancement of TREK1 channel activity by
GI-530159 is observed across all the platforms tested. Further-
more, the 50% effective concentration for enhancement of
TREK1 channels by GI-530159 is also consistent across all
the platforms tested.
There are a number of compounds that have been identi-
ﬁed that activate TREK channels (see Mathie and Veale, 2015;
Vivier et al., 2016). Fenamate compounds, such as ﬂufenamic
acid, are non-steroidal anti-inﬂammatory drugs used
clinically in the treatment of pain and are strong activators
of TREK channels (Takahira et al., 2005; Veale et al., 2014)
with ﬂufenamic acid the most effective of these compounds
(Veale et al., 2014). However, none of the fenamates are selec-
tive for TREK channels, and all either activate or block many
other ion channel types (see Mathie and Veale, 2015, also
Guinamard et al., 2013).
The dihydroacridine analogue (ML67-33) has been found
to selectively and directly activate TREK1, TREK2 and TRAAK
channels (Bagriantsev et al., 2013). Bagriantsev et al. (2013)
showed that ML67-33 acts via a gate located at (or close to)
the selectivity ﬁlter of the channels, which has been pro-
posed as the site where many different activators converge
to regulate channel activity (Schewe et al., 2016; Lolicato
et al., 2017). Enhancement of TREK1 and TREK2 channels is
also seen with aristolochic acid, found in a number of plant
extracts used to treat pain, and activation by aristolochic acid
may occur through a similar mechanism to ML67-33 (see
Veale and Mathie, 2016). However, aristolochic acid is not
selective for TREK channels with effects on a range of other
K2P channels (Veale and Mathie, 2016).
Another group of compounds that enhance the activity of
TREK1 channels is caffeic acid esters [such as cinnamyl 1,3,4-
Figure 7
Effect of GI-530159 on small DRG neuron ﬁring properties. (A) Normal ﬁring of individual DRG neuron in response to current injection (black
trace) is inhibited by GI-530159 (1 μM, red trace). (B, C) GI-530159 inhibits action potential ﬁring in some small DRG neurons. (D–F) GI-
530159 (1 μM) hyperpolarizes the membrane potential of small DRG neurons. In (D), membrane potential in each individual neuron is
hyperpolarized from 53.6 ± 1.5 to 57.1 ± 1.5 mV (n = 14 individual neurons, P < 0.05, paired t-test) by GI-530159 (1 μM). In (E), the average
membrane potential in neurons from a given rat is signiﬁcantly hyperpolarized from54.0 ± 2.0 to57.8 ± 1.4 mV (n = 7 rats, P < 0.05, paired t-
test, Figure 7D) by GI-530159 (1 μM). In (C, F), six neurons with clear inhibition of ﬁring are shown in red, and six neurons where there was no
inhibition of ﬁring are in blue. Two neurons, which were not clearly deﬁned, are shown in grey. Each recorded neuron was from an independent
coverslip, and the 14 neurons were taken from seven independent preparations of DRG neurons.
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dihydroxy-α-cyanocinnamate (CDC) and caffeic acid
phenylethyl ester (CAPE)]. It has been suggested that caffeic
acid derivatives bind to an external site to produce their
effects on TREK1 channels, since activity was retained when
the compounds were applied externally in outside-out patch
recordings (Danthi et al., 2004). More recently, a range of
substituted caffeic acid esters based on a hybrid of CDC and
CAPE have been developed, the most promising of which
(compound 12U) both enhances the activity of TREK1 chan-
nels and displays potent analgesic activity in vivo (Rodrigues
et al., 2014). Very recently, these authors have extended this
work by developing a series of substituted acrylic acids, which
activate TREK1 channels and show anti-nociceptive activity
in vivo (Vivier et al., 2017). Also recently, Dadi et al. (2017)
have shown that PG F2α and a number of other small mole-
cules activate TREK2 channels and stimulate K2P currents in
a proportion of DRG neurons. 2-Aminoethoxydiphenyl
borate has also been suggested to be a selective activator of
TREK2 channels (Zhuo et al., 2015).
Although previous expression studies, including protein
expression studies (Maingret et al., 2000), suggest that TREK1
channels are expressed in both small-sized andmedium-sized
DRG neurons (Maingret et al., 2000; Talley et al., 2001; Alloui
et al., 2006; Dedman et al., 2009), both single-channel and
whole-cell patch recordings suggested that TREK2 channels
may also contribute to the background current present in
these cells (e.g. Kang and Kim, 2006). Recently, TREK2
channels have been shown to be selectively expressed in IB4
binding, non-peptidergic C nociceptors (Acosta et al., 2014).
TREK2 channels contribute to the resting membrane poten-
tial of these neurons, since siRNA against TREK2 depolarized
the neurons by 10 mV (Acosta et al., 2014).
To try to clarify the expression of different TREK channels
in different populations of rat DRG neurons, we used single-
cell RNA sequencing. From 120 neurons identiﬁed, we found
quite variable expression levels of each TREK channel sub-
type from cell to cell. It is important to note that expression
from single-cell sequencing can be biased to detect highly
expressing transcripts, which can lead to biases in classiﬁca-
tion. The complexity of expression we have observed in rat
DRGs is consistent with a recent classiﬁcation of mouse
DRG neurons from transcriptome analysis (Usoskin et al.,
2015). In that study, unbiased classiﬁcation of mouse sensory
neuron types by large-scale single-cell RNA sequencing
revealed at least 11 types of sensory neuron, which serves to
illustrate the diversity of sensory types and the cellular com-
plexity underlying somatic sensation (Usoskin et al., 2015).
Current-clamp recordings from small DRG neurons in
culture, which from our single-cell RNA sequencing would
be likely to express signiﬁcant TREK1 channels, showed that
GI-530139 signiﬁcantly hyperpolarized the neurons. This
led to a reduction in cell ﬁring frequency; however, this latter
effect was variable with frequency reduced or abolished in
57% of cells but unaffected in 43% of cells. From effects on
ﬁring, it appears that the neurons fall into two groups, those
where ﬁring is blocked and those where there is little effect
of GI-530139, with about half the neurons in each group.
This suggests, either, that these small DRG neurons are a
heterogeneous group (consistent with the variations seen in
TREK channel expression from cell to cell, above) or, alterna-
tively, that the threshold for an effect on ﬁring is slightly
different from one group of neurons to another and, at the
concentration chosen (1 μM), GI-530139 only takes a propor-
tion of the neurons below that neuron’s particular threshold
for ﬁring.
The critical role of TREK channels in pain perception
suggests that compounds such as GI-530139, which
selectively enhance their activity, will be of considerable
value both experimentally and as potential new analgesic
agents targeting these channels (see Mathie and Veale,
2015). As shown in this study, pharmacological activation
of TREK channels hyperpolarizes the membrane potential of
DRG neurons and depresses neuronal activity. This effect will
be primarily through activation of TREK1 channels but, in a
subset of neurons, may be through activation of TREK2
channels or even heterodimer TREK1/TREK2 channels (Blin
et al., 2016; Lengyel et al., 2016; Levitz et al., 2016). This will
act to oppose noxious, excitatory stimulation of these
neurons and the subsequent activation of neuronal pain
signalling pathways.
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